SAB5600047
Anti-BRAF (V600E) antibody, Rabbit monoclonal
recombinant, expressed in HEK 293 cells, clone RM8, purified immunoglobulin
Sinónimos:
Anti-B-RAF1, Anti-B-raf, Anti-BRAF-1, Anti-BRAF1, Anti-NS7, Anti-RAFB1
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Código UNSPSC:
12352203
NACRES:
NA.41
En este momento no podemos mostrarle ni los precios ni la disponibilidad
Productos recomendados
recombinante
expressed in HEK 293 cells
Nivel de calidad
forma del anticuerpo
purified immunoglobulin
tipo de anticuerpo
primary antibodies
clon
RM8, monoclonal
recombinant monoclonal
Formulario
buffered aqueous glycerol solution
reactividad de especies
human
concentración
~1 mg/mL
técnicas
ELISA: 0.5-2 μg/mL
immunoblotting: 0.5-2 μg/mL
immunocytochemistry: 0.5-5 μg/mL
immunohistochemistry: 0.5-5 μg/mL
isotipo
IgG
Nº de acceso NCBI
Nº de acceso UniProt
Condiciones de envío
wet ice
temp. de almacenamiento
−20°C
modificación del objetivo postraduccional
unmodified
Información sobre el gen
human ... BRAF(673)
Descripción general
BRAF (B-Raf proto-oncogene) is a serine-threonine kinase, that codes for B-Raf protein. It is located on human chromosome 7q34.
Especificidad
This antibody reacts to the BRAF V600E mutant. No cross reactivity with wild type BRAF.
Inmunógeno
Peptide corresponding to BRAF V600E mutant
Acciones bioquímicas o fisiológicas
BRAF (B-Raf proto-oncogene) participates in signaling direct cell growth. It induces tumor growth by initiating the mitogen-activated protein kinase (MAPK) pathway in various tumors like cutaneous melanoma and carcinomas of the thyroid and colon.
Características y beneficios
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Forma física
Solution in phosphate buffered saline containing 50% glycerol, 1% BSA and 0.09% sodium azide.
Cláusula de descargo de responsabilidad
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
¿No encuentra el producto adecuado?
Pruebe nuestro Herramienta de selección de productos.
Código de clase de almacenamiento
10 - Combustible liquids
Clase de riesgo para el agua (WGK)
WGK 2
Punto de inflamabilidad (°F)
Not applicable
Punto de inflamabilidad (°C)
Not applicable
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Daniel Delev et al.
Scientific reports, 10(1), 96-96 (2020-01-11)
Long-term epilepsy-associated tumors (LEATs) represent mostly benign brain tumors associated with drug-resistant epilepsy. The aim of the study was to investigate the specific transcriptional signatures of those tumors and characterize their underlying oncogenic drivers. A cluster analysis of 65 transcriptome
Maria Russi et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 180, 106311-106311 (2022-10-24)
Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2
Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E, et al.
British Journal of Cancer, 117(10), 1450-1450 (2017)
Xuhong Wang et al.
Oncology letters, 18(1), 927-935 (2019-07-11)
Keratin 19 (KRT19) is a type I cytokeratin that serves an important role in multiple types of cancer; however, little is known regarding its role in thyroid cancer. Therefore, the aim of the current study was to investigate the role
The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ, et al.
Medicine, 96(48), e8404-e8404 (2017)
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico
